Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIGREC pharmacokinetic study in heart transplant recipients
2006-006832-23Phase 4Active
- Sponsor
- CHU de Limoges
- Start
- Mar 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine, tacrolimus, mycophenolate mofetil, mycophenolic acid and everolimus in Cardiac Rejection, sponsored by CHU de Limoges. Primary endpoint: Pharmacokinetic model development. Started Mar 2007; status: active.
02
Drugs
cyclosporinetacrolimusmycophenolate mofetilmycophenolic acideverolimus
03
Conditions
Cardiac Rejection
Beyond the preview
Go deeper on 2006-006832-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006832-23.